These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 7508131

  • 1. Organic nitrates and compounds that increase intraplatelet cyclic guanosine monophosphate (cGMP) levels enhance the antiaggregating effects of the stable prostacyclin analogue iloprost.
    Anfossi G, Massucco P, Mularoni E, Cavalot F, Mattiello L, Trovati M.
    Prostaglandins Leukot Essent Fatty Acids; 1993 Nov; 49(5):839-45. PubMed ID: 7508131
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity.
    Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A, Trovati M.
    Eur J Clin Invest; 2004 Jul; 34(7):482-9. PubMed ID: 15255785
    [Abstract] [Full Text] [Related]

  • 4. Glyceryl trinitrate enhances the adenosine-induced inhibition of platelet responses: a mechanism potentially involved in the in vivo anti-aggregating effects of organic nitrates.
    Anfossi G, Massucco P, Piretto V, Mularoni E, Cavalot F, Mattiello L, Trovati M.
    Clin Exp Pharmacol Physiol; 1995 Nov; 22(11):803-11. PubMed ID: 8593734
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin.
    Russo I, Traversa M, Bonomo K, De Salve A, Mattiello L, Del Mese P, Doronzo G, Cavalot F, Trovati M, Anfossi G.
    Obesity (Silver Spring); 2010 Apr; 18(4):788-97. PubMed ID: 19834474
    [Abstract] [Full Text] [Related]

  • 7. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
    Negrescu EV, Grünberg B, Kratzer MA, Lorenz R, Siess W.
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.
    Anfossi G, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, Cavalot F, Trovati M.
    Diabetes Care; 1998 Jan; 21(1):121-6. PubMed ID: 9538982
    [Abstract] [Full Text] [Related]

  • 11. Synergistic interaction of adenylate cyclase activators and nitric oxide donor SIN-1 on platelet cyclic AMP.
    Fisch A, Michael-Hepp J, Meyer J, Darius H.
    Eur J Pharmacol; 1995 May 26; 289(3):455-61. PubMed ID: 7556414
    [Abstract] [Full Text] [Related]

  • 12. Insulin increases guanosine-3',5'-cyclic monophosphate in human platelets. A mechanism involved in the insulin anti-aggregating effect.
    Trovati M, Massucco P, Mattiello L, Mularoni E, Cavalot F, Anfossi G.
    Diabetes; 1994 Aug 26; 43(8):1015-9. PubMed ID: 7518780
    [Abstract] [Full Text] [Related]

  • 13. Iloprost and echistatin protect platelets during simulated extracorporeal circulation.
    Bernabei A, Gikakis N, Kowalska MA, Niewiarowski S, Edmunds LH.
    Ann Thorac Surg; 1995 Jan 26; 59(1):149-53. PubMed ID: 7529485
    [Abstract] [Full Text] [Related]

  • 14. Interplay between milrinone and adenosine in the inhibition of human platelet response.
    Anfossi G, Massucco P, Piretto V, Mularoni E, Cavalot F, Mattiello L, Trovati M.
    Gen Pharmacol; 1996 Oct 26; 27(7):1149-54. PubMed ID: 8981060
    [Abstract] [Full Text] [Related]

  • 15. Platelet resistance to the antiaggregating effect of N-acetyl-L-cysteine in obese, insulin-resistant subjects.
    Anfossi G, Russo I, Massucco P, Mattiello L, Trovati M.
    Thromb Res; 2003 Apr 15; 110(1):39-46. PubMed ID: 12877907
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Studies on the importance of the proposed release of nitric oxide from platelets.
    Mollace V, Salvemini D, Vane J.
    Thromb Res; 1991 Dec 01; 64(5):533-42. PubMed ID: 1725563
    [Abstract] [Full Text] [Related]

  • 18. Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.
    Chirkov YY, Chirkova LP, Horowitz JD.
    Naunyn Schmiedebergs Arch Pharmacol; 1996 Oct 01; 354(4):520-5. PubMed ID: 8897457
    [Abstract] [Full Text] [Related]

  • 19. Platelet cAMP and cGMP in essential hypertension.
    Hoffmann G, Göbel BO, Harbrecht U, Vetter H, Düsing R.
    Am J Hypertens; 1992 Nov 01; 5(11):847-50. PubMed ID: 1280952
    [Abstract] [Full Text] [Related]

  • 20. Adenosine diphosphate-induced aggregation is enhanced in platelets obtained from patients with thrombotic primary antiphospholipid syndrome (t-PAPS): Role of P2Y12 -cAMP signaling pathway.
    Leonardi GR, Lescano CH, Costa JL, Mazetto B, Orsi FA, Monica FZ.
    J Thromb Haemost; 2022 Jul 01; 20(7):1699-1711. PubMed ID: 35395698
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.